 Eduardo Davila
Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 7 | 2024 | 722 | 2.000 |
Why?
| | Antigens, Neoplasm | 5 | 2024 | 308 | 1.770 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 3 | 2020 | 27 | 1.550 |
Why?
| | T-Lymphocytes | 8 | 2024 | 1921 | 1.320 |
Why?
| | CD8-Positive T-Lymphocytes | 7 | 2021 | 840 | 1.320 |
Why?
| | Myeloid Differentiation Factor 88 | 7 | 2021 | 95 | 1.260 |
Why?
| | Toll-Like Receptor 2 | 4 | 2016 | 112 | 1.190 |
Why?
| | Melanoma, Experimental | 5 | 2016 | 108 | 1.140 |
Why?
| | Neoplasms | 7 | 2025 | 2460 | 1.100 |
Why?
| | Chromones | 3 | 2024 | 45 | 0.960 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 15 | 0.940 |
Why?
| | Morpholines | 3 | 2024 | 122 | 0.900 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 875 | 0.860 |
Why?
| | Immunotherapy, Adoptive | 6 | 2025 | 295 | 0.810 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2021 | 699 | 0.790 |
Why?
| | Cancer Vaccines | 2 | 2019 | 163 | 0.770 |
Why?
| | Cell Engineering | 1 | 2021 | 9 | 0.750 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 140 | 0.750 |
Why?
| | Apoptosis | 6 | 2020 | 2425 | 0.730 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 25 | 0.700 |
Why?
| | Immunotherapy | 3 | 2021 | 586 | 0.670 |
Why?
| | Caspase 3 | 1 | 2020 | 229 | 0.640 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1558 | 0.640 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 620 | 0.620 |
Why?
| | Calcium-Binding Proteins | 1 | 2020 | 209 | 0.620 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2023 | 591 | 0.620 |
Why?
| | CD8 Antigens | 2 | 2017 | 76 | 0.620 |
Why?
| | Dendritic Cells | 2 | 2019 | 475 | 0.610 |
Why?
| | Mice | 22 | 2025 | 16574 | 0.600 |
Why?
| | Signal Transduction | 5 | 2021 | 4812 | 0.590 |
Why?
| | Mice, Inbred NOD | 7 | 2025 | 586 | 0.590 |
Why?
| | Phenylurea Compounds | 2 | 2017 | 89 | 0.570 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 431 | 0.550 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1343 | 0.540 |
Why?
| | Mice, SCID | 6 | 2025 | 350 | 0.540 |
Why?
| | Toll-Like Receptor 1 | 1 | 2016 | 12 | 0.530 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2016 | 25 | 0.520 |
Why?
| | Animals | 25 | 2025 | 34487 | 0.510 |
Why?
| | Genetic Variation | 1 | 2021 | 933 | 0.510 |
Why?
| | Gamma Rays | 2 | 2023 | 53 | 0.490 |
Why?
| | Toll-Like Receptors | 3 | 2012 | 179 | 0.490 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2008 | 168 | 0.490 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2025 | 809 | 0.480 |
Why?
| | Flagellin | 1 | 2015 | 17 | 0.480 |
Why?
| | Cell Line, Tumor | 8 | 2025 | 3168 | 0.470 |
Why?
| | Recombinant Fusion Proteins | 1 | 2017 | 634 | 0.470 |
Why?
| | Antineoplastic Agents | 3 | 2015 | 2041 | 0.450 |
Why?
| | Pyridines | 1 | 2017 | 474 | 0.430 |
Why?
| | Benzimidazoles | 1 | 2015 | 158 | 0.430 |
Why?
| | Lymphocyte Activation | 6 | 2019 | 1096 | 0.420 |
Why?
| | Neoplasm Proteins | 3 | 2024 | 419 | 0.410 |
Why?
| | T-Lymphocyte Subsets | 3 | 2021 | 409 | 0.410 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2025 | 210 | 0.400 |
Why?
| | Oligodeoxyribonucleotides | 2 | 2003 | 138 | 0.400 |
Why?
| | Antibodies, Monoclonal | 3 | 2012 | 1354 | 0.390 |
Why?
| | Cell Proliferation | 6 | 2020 | 2337 | 0.390 |
Why?
| | Mice, Knockout | 5 | 2024 | 2757 | 0.330 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2017 | 216 | 0.310 |
Why?
| | Adoptive Transfer | 2 | 2008 | 215 | 0.300 |
Why?
| | Thymoma | 2 | 2010 | 31 | 0.300 |
Why?
| | Cell Survival | 5 | 2017 | 1073 | 0.300 |
Why?
| | CD4-Positive T-Lymphocytes | 4 | 2007 | 1043 | 0.290 |
Why?
| | Toll-Like Receptor 9 | 1 | 2007 | 31 | 0.290 |
Why?
| | Response Elements | 1 | 2007 | 88 | 0.280 |
Why?
| | Mice, Inbred C57BL | 6 | 2017 | 5268 | 0.280 |
Why?
| | Humans | 24 | 2025 | 128019 | 0.260 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2017 | 39 | 0.260 |
Why?
| | Immunomodulation | 2 | 2017 | 90 | 0.260 |
Why?
| | Protein Kinases | 1 | 2007 | 308 | 0.250 |
Why?
| | Membrane Glycoproteins | 2 | 2025 | 467 | 0.250 |
Why?
| | Antigens, CD | 3 | 2021 | 481 | 0.240 |
Why?
| | CD47 Antigen | 1 | 2025 | 28 | 0.240 |
Why?
| | Diphtheria Toxin | 1 | 2025 | 64 | 0.230 |
Why?
| | Immunotoxins | 1 | 2025 | 54 | 0.230 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 16 | 0.220 |
Why?
| | Protein Binding | 3 | 2021 | 2105 | 0.220 |
Why?
| | Immunodominant Epitopes | 1 | 2003 | 28 | 0.210 |
Why?
| | Antigens, Differentiation | 1 | 2003 | 82 | 0.210 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2003 | 62 | 0.210 |
Why?
| | CpG Islands | 1 | 2003 | 151 | 0.200 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 74 | 0.200 |
Why?
| | Dinucleoside Phosphates | 1 | 2002 | 28 | 0.200 |
Why?
| | Mice, Transgenic | 3 | 2025 | 2066 | 0.200 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2005 | 366 | 0.200 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2023 | 62 | 0.190 |
Why?
| | Cell Communication | 2 | 2019 | 297 | 0.190 |
Why?
| | Immunoconjugates | 1 | 2003 | 101 | 0.190 |
Why?
| | Adjuvants, Immunologic | 1 | 2003 | 221 | 0.190 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 106 | 0.190 |
Why?
| | Antigen Presentation | 2 | 2017 | 205 | 0.190 |
Why?
| | CD3 Complex | 1 | 2021 | 101 | 0.180 |
Why?
| | Semaphorins | 1 | 2021 | 28 | 0.180 |
Why?
| | Skin Neoplasms | 1 | 2008 | 818 | 0.180 |
Why?
| | Disease Models, Animal | 3 | 2021 | 3936 | 0.170 |
Why?
| | Heterografts | 1 | 2021 | 128 | 0.170 |
Why?
| | Genetic Engineering | 1 | 2021 | 88 | 0.170 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 137 | 0.170 |
Why?
| | Immunologic Memory | 1 | 2002 | 341 | 0.170 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 538 | 0.170 |
Why?
| | Multiprotein Complexes | 1 | 2021 | 147 | 0.170 |
Why?
| | Immune System | 1 | 2021 | 176 | 0.160 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 165 | 0.160 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 31 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2021 | 331 | 0.160 |
Why?
| | Cytokines | 3 | 2012 | 1984 | 0.160 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2021 | 573 | 0.150 |
Why?
| | Leukemia | 1 | 2021 | 228 | 0.150 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 930 | 0.150 |
Why?
| | HLA-A2 Antigen | 2 | 2010 | 47 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-pim-1 | 1 | 2017 | 2 | 0.150 |
Why?
| | Jurkat Cells | 2 | 2015 | 130 | 0.140 |
Why?
| | CD55 Antigens | 1 | 2017 | 28 | 0.140 |
Why?
| | Gene Expression Profiling | 2 | 2016 | 1681 | 0.140 |
Why?
| | Gene Duplication | 1 | 2017 | 67 | 0.140 |
Why?
| | 5'-Nucleotidase | 1 | 2017 | 37 | 0.140 |
Why?
| | Genes, MHC Class I | 1 | 2017 | 33 | 0.140 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2017 | 47 | 0.140 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1421 | 0.140 |
Why?
| | Receptors, Virus | 1 | 2017 | 83 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 583 | 0.140 |
Why?
| | Carrier Proteins | 1 | 2021 | 730 | 0.140 |
Why?
| | Arthritis, Rheumatoid | 1 | 2005 | 1088 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 532 | 0.130 |
Why?
| | B7-H1 Antigen | 1 | 2017 | 189 | 0.120 |
Why?
| | Toll-Like Receptor 5 | 1 | 2015 | 14 | 0.120 |
Why?
| | TNF Receptor-Associated Factor 6 | 1 | 2015 | 4 | 0.120 |
Why?
| | Immune Tolerance | 1 | 2017 | 347 | 0.120 |
Why?
| | Nitrophenols | 1 | 2015 | 33 | 0.120 |
Why?
| | MCF-7 Cells | 1 | 2015 | 115 | 0.120 |
Why?
| | Vaccination | 1 | 2003 | 1343 | 0.120 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 60 | 0.110 |
Why?
| | Neoplasm Transplantation | 1 | 2015 | 257 | 0.110 |
Why?
| | Vincristine | 1 | 2015 | 109 | 0.110 |
Why?
| | Protein Stability | 1 | 2015 | 159 | 0.110 |
Why?
| | Drug Synergism | 1 | 2015 | 356 | 0.110 |
Why?
| | Female | 9 | 2025 | 68016 | 0.110 |
Why?
| | Interferon-gamma | 2 | 2010 | 760 | 0.110 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 196 | 0.110 |
Why?
| | Flow Cytometry | 1 | 2017 | 1140 | 0.110 |
Why?
| | Antifreeze Proteins | 1 | 2013 | 1 | 0.110 |
Why?
| | Gadus morhua | 1 | 2013 | 1 | 0.110 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2015 | 360 | 0.110 |
Why?
| | Fish Proteins | 1 | 2013 | 10 | 0.110 |
Why?
| | Galectin 3 | 1 | 2013 | 20 | 0.100 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2012 | 20 | 0.100 |
Why?
| | Receptors, Antigen | 1 | 2012 | 15 | 0.100 |
Why?
| | Cell Growth Processes | 1 | 2012 | 52 | 0.100 |
Why?
| | Piperazines | 1 | 2015 | 332 | 0.100 |
Why?
| | HEK293 Cells | 1 | 2015 | 681 | 0.100 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1286 | 0.090 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1198 | 0.090 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2011 | 6 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2016 | 1185 | 0.090 |
Why?
| | Sulfonamides | 1 | 2015 | 494 | 0.090 |
Why?
| | Gene Expression | 1 | 2016 | 1454 | 0.090 |
Why?
| | Enzyme Activation | 1 | 2012 | 796 | 0.090 |
Why?
| | Perforin | 1 | 2010 | 19 | 0.090 |
Why?
| | Male | 6 | 2021 | 62757 | 0.090 |
Why?
| | Cell Movement | 1 | 2015 | 933 | 0.090 |
Why?
| | Granzymes | 1 | 2010 | 45 | 0.090 |
Why?
| | Mutation | 1 | 2021 | 3682 | 0.080 |
Why?
| | Cells, Cultured | 1 | 2017 | 4006 | 0.080 |
Why?
| | Biomarkers | 1 | 2021 | 3874 | 0.080 |
Why?
| | T-Box Domain Proteins | 1 | 2010 | 96 | 0.080 |
Why?
| | Receptors, Immunologic | 1 | 2011 | 215 | 0.080 |
Why?
| | Protein Kinase C | 1 | 2010 | 255 | 0.080 |
Why?
| | Graft vs Host Disease | 1 | 2011 | 238 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2010 | 356 | 0.070 |
Why?
| | Transcription Factors | 1 | 2016 | 1628 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1681 | 0.070 |
Why?
| | Checkpoint Kinase 2 | 1 | 2007 | 23 | 0.070 |
Why?
| | Checkpoint Kinase 1 | 1 | 2007 | 31 | 0.070 |
Why?
| | Whole-Body Irradiation | 1 | 2007 | 75 | 0.070 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2010 | 380 | 0.070 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2007 | 37 | 0.070 |
Why?
| | Radiation Tolerance | 1 | 2007 | 97 | 0.070 |
Why?
| | DNA Repair | 1 | 2007 | 205 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2013 | 888 | 0.060 |
Why?
| | Antigens | 1 | 2007 | 353 | 0.060 |
Why?
| | Ligands | 1 | 2007 | 616 | 0.060 |
Why?
| | B7-2 Antigen | 1 | 2005 | 26 | 0.060 |
Why?
| | CD28 Antigens | 1 | 2005 | 48 | 0.060 |
Why?
| | CD56 Antigen | 1 | 2005 | 37 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 1011 | 0.060 |
Why?
| | Antigen-Presenting Cells | 1 | 2005 | 150 | 0.060 |
Why?
| | Clone Cells | 1 | 2005 | 255 | 0.060 |
Why?
| | Cell Cycle | 1 | 2007 | 580 | 0.060 |
Why?
| | Synovial Membrane | 1 | 2005 | 90 | 0.060 |
Why?
| | Immunophenotyping | 1 | 2005 | 309 | 0.050 |
Why?
| | Thymus Neoplasms | 1 | 2003 | 22 | 0.050 |
Why?
| | Abatacept | 1 | 2003 | 46 | 0.050 |
Why?
| | Vaccines, Subunit | 1 | 2003 | 47 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2003 | 87 | 0.050 |
Why?
| | CD4 Antigens | 1 | 2003 | 138 | 0.050 |
Why?
| | Down-Regulation | 1 | 2005 | 630 | 0.050 |
Why?
| | Lymphocyte Count | 1 | 2002 | 150 | 0.050 |
Why?
| | Tretinoin | 1 | 2023 | 127 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 29 | 0.050 |
Why?
| | Graft vs Tumor Effect | 1 | 2021 | 8 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 2508 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 68 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 85 | 0.040 |
Why?
| | Fibroblasts | 1 | 2005 | 934 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 389 | 0.040 |
Why?
| | Cell Line | 1 | 2005 | 2736 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2042 | 0.040 |
Why?
| | Base Sequence | 1 | 2002 | 2134 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2820 | 0.040 |
Why?
| | Benzothiazoles | 1 | 2017 | 32 | 0.040 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2017 | 67 | 0.040 |
Why?
| | Proteolysis | 1 | 2017 | 162 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2017 | 451 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 582 | 0.030 |
Why?
| | Antigens, Tumor-Associated, Carbohydrate | 1 | 2013 | 7 | 0.030 |
Why?
| | Proteome | 1 | 2017 | 430 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3039 | 0.020 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2013 | 97 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 289 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 608 | 0.020 |
Why?
| | Aged | 1 | 2021 | 21892 | 0.010 |
Why?
| | Middle Aged | 1 | 2021 | 30812 | 0.010 |
Why?
|
|
Davila's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|